Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | Unknown | — |
The patent received the second dose of RabAvert vaccine on day 10; Case reference number US-BN-2024-002455 is a spontaneous case initially received from other health care professional via Med Communications (reference number USBAV24-2313) on 10-Sep-2024 and concerns a patient of unknown demographics. The patient's medical history and concomitant medication details were not provided. On an unspecified date, reported as day zero, the patient received the first dose of RabAvert (batch number: unknown), at an unknown dose, route, or site of administration, for pre-exposure prophylaxis. On an unspecified date, reported as day ten, the patient received the second dose of RabAvert (batch number: unknown), at an unknown dose, route, or site of administration (explicitly coded as 'Inappropriate schedule of vaccine administered'). On an unspecified date, reported as day 28, the patient received the third dose of RabAvert (batch number: unknown), at an unknown dose, route, or site of administration. At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. No further information was provided.; Reporter's Comments: A patient of unknown demographics received the second dose of RabAvert for pre-exposure prophylaxis on the day 10 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown demographics received the second dose of RabAvert for pre-exposure prophylaxis on the day 10 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None